Exelixis, Inc. (NASDAQ:EXEL) EVP Sells $352,700.00 in Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $35.27, for a total value of $352,700.00. Following the transaction, the executive vice president now directly owns 278,665 shares of the company’s stock, valued at $9,828,514.55. This represents a 3.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Exelixis Stock Up 0.2 %

Shares of EXEL stock traded up $0.07 during trading on Tuesday, hitting $36.45. The company had a trading volume of 1,307,745 shares, compared to its average volume of 2,073,519. The stock’s 50-day moving average is $30.08 and its two-hundred day moving average is $25.73. The stock has a market capitalization of $10.41 billion, a price-to-earnings ratio of 23.37, a price-to-earnings-growth ratio of 0.90 and a beta of 0.51. Exelixis, Inc. has a 52 week low of $19.20 and a 52 week high of $36.72.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. During the same quarter in the prior year, the firm earned $0.10 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. On average, research analysts predict that Exelixis, Inc. will post 1.69 EPS for the current fiscal year.

Institutional Trading of Exelixis

A number of hedge funds have recently bought and sold shares of EXEL. Tri Ri Asset Management Corp purchased a new stake in Exelixis during the third quarter valued at about $4,396,000. Tidal Investments LLC lifted its stake in shares of Exelixis by 2.3% in the 3rd quarter. Tidal Investments LLC now owns 36,366 shares of the biotechnology company’s stock valued at $944,000 after purchasing an additional 823 shares during the period. Sanctuary Advisors LLC boosted its holdings in shares of Exelixis by 42.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 39,261 shares of the biotechnology company’s stock valued at $1,019,000 after buying an additional 11,757 shares in the last quarter. TD Private Client Wealth LLC boosted its stake in Exelixis by 376.8% during the third quarter. TD Private Client Wealth LLC now owns 9,756 shares of the biotechnology company’s stock worth $253,000 after acquiring an additional 7,710 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in shares of Exelixis in the 3rd quarter worth approximately $264,000. Institutional investors own 85.27% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on EXEL. Truist Financial upped their price objective on shares of Exelixis from $33.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. BMO Capital Markets raised their price target on shares of Exelixis from $29.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. UBS Group assumed coverage on Exelixis in a research note on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price objective for the company. Oppenheimer reissued an “outperform” rating and issued a $29.00 price target on shares of Exelixis in a research note on Tuesday, July 30th. Finally, Wells Fargo & Company increased their price target on Exelixis from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $31.44.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.